Astera Labs vs Viavi Solutions
ALAB and VIAV side by side, both in electronic components and accessories. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALAB and VIAV compare
Astera Labs is the larger company, worth 5.0 times as much as Viavi Solutions ($36.7B against $7.3B).
Astera Labs grew revenue faster over the last twelve months (98.5% versus 40.0% for Viavi Solutions).
Astera Labs keeps more of each dollar of sales as profit, with a net margin of 30.7% compared with −2.0% at Viavi Solutions.
Astera Labs scores higher on the StockData Score (12 against 7 for Viavi Solutions), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALAB | VIAV |
|---|---|---|
| Size and price | ||
| Market cap | $36.7B | $7.3B |
| Share price | $211.60 | $29.77 |
| Change, 1 year | 46.6% | 76.3% |
| Change, 5 years | – | 96.5% |
| Beta (5Y) | 4.20 | 1.48 |
| Employees | 756 | 4,100 |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 0 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 105× | – |
| P/S | 30.5× | 4.8× (better) |
| P/B | 21.3× | 5.1× (better) |
| EV/EBITDA | 124× | 66.0× (better) |
| P/FCF | 133× | 88.7× (better) |
| FCF yield | 0.75% | 1.1% (better) |
| Fair value | $54.45 | $14.82 |
| Margin of safety | −289% | −101% (better) |
| Growth | ||
| Revenue growth (TTM) | 98.5% (better) | 40.0% |
| Revenue growth, 5Y average | – | 4.8% |
| Net income growth (TTM) | 269% (better) | −187% |
| EPS growth (TTM) | – | −187% |
| Profitability | ||
| Gross margin | 75.1% (better) | 57.7% |
| Operating margin | 22.8% (better) | 6.9% |
| Net margin | 30.7% (better) | −2.0% |
| FCF margin | 23.0% (better) | 5.5% |
| Return on equity | 25.8% (better) | −2.7% |
| Return on invested capital | 101% (better) | 6.4% |
| Financial health | ||
| Debt / equity | 0.00 | 0.17 (better) |
| Net debt / EBITDA | – | −3.85 |
| Interest coverage | – | 2.2× |
| Current ratio | 10.05 (better) | 1.85 |
| Altman Z-score | 109.22 (better) | −31.61 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 0.41% |
| Shareholder yield | 0.00% | 0.41% (better) |
| Ownership | ||
| Held by institutions | 73.6% | 97.5% |
| Held by insiders | 11.4% | 1.3% |
| Insider net buying, 12 months | −$758M | −$57.8M (better) |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 5.2% | 4.8% |
Go deeper
- ALAB stock overview
- ALAB income statement
- ALAB valuation and score
- VIAV stock overview
- VIAV income statement
- VIAV valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.